We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02402309
Recruitment Status : Completed
First Posted : March 30, 2015
Results First Posted : December 13, 2022
Last Update Posted : December 13, 2022
Information provided by (Responsible Party):
Aldeyra Therapeutics, Inc.

Brief Summary:

This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to Sjögren- Larsson Syndrome (SLS).

NS2 is expected to trap fatty aldehydes that are pathogenic in SLS patients, and thereby diminish the lipid-aldehyde adduct formation that likely results in ichthyosis associated with SLS, and potentially reduce the mild dermal inflammation characteristic of SLS.

Condition or disease Intervention/treatment Phase
Sjögren-Larsson Syndrome Drug: Active topical NS2 1% dermatologic cream Drug: Vehicle placebo 0.0% NS2 dermatologic cream Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Study Start Date : March 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Active topical NS2 1% dermatologic cream
NS2 1% topical cream for dermal application
Drug: Active topical NS2 1% dermatologic cream
Placebo Comparator: Topical vehicle dermatologic
Vehicle placebo for dermal application
Drug: Vehicle placebo 0.0% NS2 dermatologic cream

Primary Outcome Measures :
  1. Number of Participants Experiencing a Serious Adverse Event (SAE). [ Time Frame: The safety assessment period is approximately 9 weeks. ]
  2. Number of Participants Experiencing an Adverse Event Leading to Discontinuation. [ Time Frame: The safety assessment period is approximately 9 weeks. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genetically-confirmed diagnosis of SLS
  • Active ichthyosis on the lower extremities that is determined to be at least moderate severity

Exclusion Criteria:

  • Evidence of an active infection
  • Currently receiving immunosuppressive therapy, including intermittent or low-dose corticosteroids and is not able or willing to suspend from 2 weeks before and during the study
  • Currently receiving systemic or topical retinoids, other topically applied drugs, or other supplements that could interfere with dermatologic examination findings
  • Received an investigational systemic or topically administered drug within 30 days before screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02402309

Layout table for location information
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, Pennsylvania
Penn State Hershey Medical Center - Department of Dermatology
Hershey, Pennsylvania, United States, 17033
United States, Virginia
Pediatric and General Dermatology
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Aldeyra Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: William B. Rizzo, MD University of Nebraska
Layout table for additonal information
Responsible Party: Aldeyra Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02402309    
Other Study ID Numbers: NS-003
First Posted: March 30, 2015    Key Record Dates
Results First Posted: December 13, 2022
Last Update Posted: December 13, 2022
Last Verified: November 2022
Keywords provided by Aldeyra Therapeutics, Inc.:
Sjögren-Larsson Syndrome
FALDH Deficiency
Fatty Alcohol:NAD+ Oxidoreductase Deficiency
Fatty Aldehyde Dehydrogenase Deficiency Disease
Congenital Icthyosis Mental Retardation Spasticity Syndrome
Spastic Neurologic Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Sjogren-Larsson Syndrome
Pathologic Processes
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Skin Abnormalities
Congenital Abnormalities
Infant, Newborn, Diseases
Skin Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn